Jump to Main Content
- Zhang, Chuanbao, et al. Show all 31 Authors
- Cell 2018 v.175 no.6 pp. 1665-1678.e18
- adverse effects; blood-brain barrier; brain neoplasms; clinical trials; enzyme inhibitors; glioblastoma; models; mutation; neoplasm cells; patients; permeability; prognosis; therapeutics
- ... Low-grade gliomas almost invariably progress into secondary glioblastoma (sGBM) with limited therapeutic option and poorly understood mechanism. By studying the mutational landscape of 188 sGBMs, we find significant enrichment of TP53 mutations, somatic hypermutation, MET-exon-14-skipping (METex14), PTPRZ1-MET (ZM) fusions, and MET amplification. Strikingly, METex14 frequently co-occurs with ZM fu ...